IBDEI01E ; ; 12-JAN-2012
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JAN 12, 2012
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1451,2)
 ;;=^295722
 ;;^UTILITY(U,$J,358.3,1452,0)
 ;;=250.00^^18^109^3
 ;;^UTILITY(U,$J,358.3,1452,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1452,1,1,0)
 ;;=1^250.00
 ;;^UTILITY(U,$J,358.3,1452,1,2,0)
 ;;=2^DIABETES II
 ;;^UTILITY(U,$J,358.3,1452,2)
 ;;=^331779
 ;;^UTILITY(U,$J,358.3,1453,0)
 ;;=V67.51^^18^109^6
 ;;^UTILITY(U,$J,358.3,1453,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1453,1,1,0)
 ;;=1^V67.51
 ;;^UTILITY(U,$J,358.3,1453,1,2,0)
 ;;=2^HI-RISK RX F/U EXAM,NEC
 ;;^UTILITY(U,$J,358.3,1453,2)
 ;;=^295577
 ;;^UTILITY(U,$J,358.3,1454,0)
 ;;=V14.9^^18^109^9
 ;;^UTILITY(U,$J,358.3,1454,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1454,1,1,0)
 ;;=1^V14.9
 ;;^UTILITY(U,$J,358.3,1454,1,2,0)
 ;;=2^HX-DRUG ALLERGY NOS
 ;;^UTILITY(U,$J,358.3,1454,2)
 ;;=^295282
 ;;^UTILITY(U,$J,358.3,1455,0)
 ;;=V15.81^^18^109^8
 ;;^UTILITY(U,$J,358.3,1455,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1455,1,1,0)
 ;;=1^V15.81
 ;;^UTILITY(U,$J,358.3,1455,1,2,0)
 ;;=2^HX OF PAST NONCOMPLIANCE
 ;;^UTILITY(U,$J,358.3,1455,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,1456,0)
 ;;=V15.81^^18^109^7
 ;;^UTILITY(U,$J,358.3,1456,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1456,1,1,0)
 ;;=1^V15.81
 ;;^UTILITY(U,$J,358.3,1456,1,2,0)
 ;;=2^HX OF NONCOMPLIANCE
 ;;^UTILITY(U,$J,358.3,1456,2)
 ;;=^83799
 ;;^UTILITY(U,$J,358.3,1457,0)
 ;;=401.9^^18^109^12
 ;;^UTILITY(U,$J,358.3,1457,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1457,1,1,0)
 ;;=1^401.9
 ;;^UTILITY(U,$J,358.3,1457,1,2,0)
 ;;=2^HYPERTENSION NOS
 ;;^UTILITY(U,$J,358.3,1457,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,1458,0)
 ;;=V58.61^^18^109^13
 ;;^UTILITY(U,$J,358.3,1458,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1458,1,1,0)
 ;;=1^V58.61
 ;;^UTILITY(U,$J,358.3,1458,1,2,0)
 ;;=2^L/T (CURRENT) USE - ANTICOAG
 ;;^UTILITY(U,$J,358.3,1458,2)
 ;;=^303459
 ;;^UTILITY(U,$J,358.3,1459,0)
 ;;=V65.19^^18^109^17
 ;;^UTILITY(U,$J,358.3,1459,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1459,1,1,0)
 ;;=1^V65.19
 ;;^UTILITY(U,$J,358.3,1459,1,2,0)
 ;;=2^PERSON CONSULT FOR ANOTH
 ;;^UTILITY(U,$J,358.3,1459,2)
 ;;=^329985
 ;;^UTILITY(U,$J,358.3,1460,0)
 ;;=272.4^^18^109^11
 ;;^UTILITY(U,$J,358.3,1460,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1460,1,1,0)
 ;;=1^272.4
 ;;^UTILITY(U,$J,358.3,1460,1,2,0)
 ;;=2^HYPERLIPIDEMIA NOS
 ;;^UTILITY(U,$J,358.3,1460,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,1461,0)
 ;;=285.29^^18^109^1
 ;;^UTILITY(U,$J,358.3,1461,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1461,1,1,0)
 ;;=1^285.29
 ;;^UTILITY(U,$J,358.3,1461,1,2,0)
 ;;=2^ANEMIA IN CHRONIC ILLNESS
 ;;^UTILITY(U,$J,358.3,1461,2)
 ;;=^334228
 ;;^UTILITY(U,$J,358.3,1462,0)
 ;;=585.6^^18^109^5
 ;;^UTILITY(U,$J,358.3,1462,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1462,1,1,0)
 ;;=1^585.6
 ;;^UTILITY(U,$J,358.3,1462,1,2,0)
 ;;=2^ESRD
 ;;^UTILITY(U,$J,358.3,1462,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,1463,0)
 ;;=V58.69^^18^109^14
 ;;^UTILITY(U,$J,358.3,1463,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1463,1,1,0)
 ;;=1^V58.69
 ;;^UTILITY(U,$J,358.3,1463,1,2,0)
 ;;=2^L/T CURRENT USE OF OTHER MEDS
 ;;^UTILITY(U,$J,358.3,1463,2)
 ;;=^303460
 ;;^UTILITY(U,$J,358.3,1464,0)
 ;;=V58.61^^18^110^1
 ;;^UTILITY(U,$J,358.3,1464,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1464,1,1,0)
 ;;=1^V58.61
 ;;^UTILITY(U,$J,358.3,1464,1,2,0)
 ;;=2^L/T (CURRENT) USE - ANTICOAG
 ;;^UTILITY(U,$J,358.3,1464,2)
 ;;=^303459
 ;;^UTILITY(U,$J,358.3,1465,0)
 ;;=427.31^^18^110^2
 ;;^UTILITY(U,$J,358.3,1465,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1465,1,1,0)
 ;;=1^427.31
 ;;^UTILITY(U,$J,358.3,1465,1,2,0)
 ;;=2^ATRIAL FIBRILLATION
 ;;^UTILITY(U,$J,358.3,1465,2)
 ;;=^11378
 ;;^UTILITY(U,$J,358.3,1466,0)
 ;;=427.32^^18^110^3
 ;;^UTILITY(U,$J,358.3,1466,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1466,1,1,0)
 ;;=1^427.32
 ;;^UTILITY(U,$J,358.3,1466,1,2,0)
 ;;=2^ATRIAL FLUTTER
 ;;^UTILITY(U,$J,358.3,1466,2)
 ;;=^11387
 ;;^UTILITY(U,$J,358.3,1467,0)
 ;;=414.00^^18^110^4
 ;;^UTILITY(U,$J,358.3,1467,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1467,1,1,0)
 ;;=1^414.00
 ;;^UTILITY(U,$J,358.3,1467,1,2,0)
 ;;=2^CAD
 ;;^UTILITY(U,$J,358.3,1467,2)
 ;;=^28512
 ;;^UTILITY(U,$J,358.3,1468,0)
 ;;=425.4^^18^110^5
 ;;^UTILITY(U,$J,358.3,1468,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1468,1,1,0)
 ;;=1^425.4
 ;;^UTILITY(U,$J,358.3,1468,1,2,0)
 ;;=2^CARDIOMYOPATHY
 ;;^UTILITY(U,$J,358.3,1468,2)
 ;;=^87808
 ;;^UTILITY(U,$J,358.3,1469,0)
 ;;=V65.49^^18^110^6
 ;;^UTILITY(U,$J,358.3,1469,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1469,1,1,0)
 ;;=1^V65.49
 ;;^UTILITY(U,$J,358.3,1469,1,2,0)
 ;;=2^COUNSELING
 ;;^UTILITY(U,$J,358.3,1469,2)
 ;;=^303471
 ;;^UTILITY(U,$J,358.3,1470,0)
 ;;=V43.3^^18^110^7
 ;;^UTILITY(U,$J,358.3,1470,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1470,1,1,0)
 ;;=1^V43.3
 ;;^UTILITY(U,$J,358.3,1470,1,2,0)
 ;;=2^HEART VALVE REPLACEMENT
 ;;^UTILITY(U,$J,358.3,1470,2)
 ;;=^295440
 ;;^UTILITY(U,$J,358.3,1471,0)
 ;;=V67.51^^18^110^8
 ;;^UTILITY(U,$J,358.3,1471,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1471,1,1,0)
 ;;=1^V67.51
 ;;^UTILITY(U,$J,358.3,1471,1,2,0)
 ;;=2^HI-RISK RX F-U EXAM, NEC
 ;;^UTILITY(U,$J,358.3,1471,2)
 ;;=^295577
 ;;^UTILITY(U,$J,358.3,1472,0)
 ;;=V12.59^^18^110^9
 ;;^UTILITY(U,$J,358.3,1472,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1472,1,1,0)
 ;;=1^V12.59
 ;;^UTILITY(U,$J,358.3,1472,1,2,0)
 ;;=2^HX OF CIRCULATORY DISEASE
 ;;^UTILITY(U,$J,358.3,1472,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,1473,0)
 ;;=V12.51^^18^110^10
 ;;^UTILITY(U,$J,358.3,1473,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1473,1,1,0)
 ;;=1^V12.51
 ;;^UTILITY(U,$J,358.3,1473,1,2,0)
 ;;=2^HX OF THROMBOSIS/EMBOLISM
 ;;^UTILITY(U,$J,358.3,1473,2)
 ;;=^303397
 ;;^UTILITY(U,$J,358.3,1474,0)
 ;;=272.4^^18^110^11
 ;;^UTILITY(U,$J,358.3,1474,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1474,1,1,0)
 ;;=1^272.4
 ;;^UTILITY(U,$J,358.3,1474,1,2,0)
 ;;=2^HYPERLIPIDEMIA NOS
 ;;^UTILITY(U,$J,358.3,1474,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,1475,0)
 ;;=401.9^^18^110^12
 ;;^UTILITY(U,$J,358.3,1475,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1475,1,1,0)
 ;;=1^401.9
 ;;^UTILITY(U,$J,358.3,1475,1,2,0)
 ;;=2^HYPERTENSION NOS
 ;;^UTILITY(U,$J,358.3,1475,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,1476,0)
 ;;=V68.1^^18^110^13
 ;;^UTILITY(U,$J,358.3,1476,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,1476,1,1,0)
 ;;=1^V68.1
 ;;^UTILITY(U,$J,358.3,1476,1,2,0)
 ;;=2^ISSUE REPEAT RX
 ;;^UTILITY(U,$J,358.3,1476,2)
 ;;=^295585
 ;;^UTILITY(U,$J,358.3,1477,0)
 ;;=V58.83^^19^111^1
 ;;^UTILITY(U,$J,358.3,1477,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1477,1,3,0)
 ;;=3^THERAPEUTIC DRUG MONITORING
 ;;^UTILITY(U,$J,358.3,1477,1,4,0)
 ;;=4^V58.83
 ;;^UTILITY(U,$J,358.3,1477,2)
 ;;=^322076
 ;;^UTILITY(U,$J,358.3,1478,0)
 ;;=99605^^20^112^1^^^^1
 ;;^UTILITY(U,$J,358.3,1478,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,1478,1,2,0)
 ;;=2^MTMS BY PHARM,INIT 15 MIN
 ;;^UTILITY(U,$J,358.3,1478,1,3,0)
 ;;=3^99605
 ;;^UTILITY(U,$J,358.3,1479,0)
 ;;=99607^^20^112^2^^^^1
 ;;^UTILITY(U,$J,358.3,1479,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,1479,1,2,0)
 ;;=2^MTMS BY PHARM, EA ADDL 15 MIN
 ;;^UTILITY(U,$J,358.3,1479,1,3,0)
 ;;=3^99607
 ;;^UTILITY(U,$J,358.3,1480,0)
 ;;=99606^^20^113^1^^^^1
 ;;^UTILITY(U,$J,358.3,1480,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,1480,1,2,0)
 ;;=2^MTMS BY PHARM,INIT 15 MIN
 ;;^UTILITY(U,$J,358.3,1480,1,3,0)
 ;;=3^99606
 ;;^UTILITY(U,$J,358.3,1481,0)
 ;;=99607^^20^113^2^^^^1
 ;;^UTILITY(U,$J,358.3,1481,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,1481,1,2,0)
 ;;=2^MTMS BY PHARM, EA ADDL 15 MIN
 ;;^UTILITY(U,$J,358.3,1481,1,3,0)
 ;;=3^99607
 ;;^UTILITY(U,$J,358.3,1482,0)
 ;;=98960^^20^114^1^^^^1
 ;;^UTILITY(U,$J,358.3,1482,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,1482,1,2,0)
 ;;=2^INDIVIDUAL PATIENT, EA 30 MIN
 ;;^UTILITY(U,$J,358.3,1482,1,3,0)
 ;;=3^98960
 ;;^UTILITY(U,$J,358.3,1483,0)
 ;;=98961^^20^114^2^^^^1
 ;;^UTILITY(U,$J,358.3,1483,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,1483,1,2,0)
 ;;=2^2-4 PATIENTS, EA 30 MIN
 ;;^UTILITY(U,$J,358.3,1483,1,3,0)
 ;;=3^98961
 ;;^UTILITY(U,$J,358.3,1484,0)
 ;;=98962^^20^114^3^^^^1
 ;;^UTILITY(U,$J,358.3,1484,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,1484,1,2,0)
 ;;=2^5-8 PATIENTS, EA 30 MIN
 ;;^UTILITY(U,$J,358.3,1484,1,3,0)
 ;;=3^98962
 ;;^UTILITY(U,$J,358.3,1485,0)
 ;;=V72.0^^21^115^2
 ;;^UTILITY(U,$J,358.3,1485,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1485,1,3,0)
 ;;=3^EYE VISION EXAMINATION
 ;;^UTILITY(U,$J,358.3,1485,1,4,0)
 ;;=4^V72.0
 ;;^UTILITY(U,$J,358.3,1485,2)
 ;;=^43432
 ;;^UTILITY(U,$J,358.3,1486,0)
 ;;=V72.11^^21^115^4
 ;;^UTILITY(U,$J,358.3,1486,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1486,1,3,0)
 ;;=3^HEARING EXAM-FAIL SCREEN
 ;;^UTILITY(U,$J,358.3,1486,1,4,0)
 ;;=4^V72.11
 ;;^UTILITY(U,$J,358.3,1486,2)
 ;;=^334218
 ;;^UTILITY(U,$J,358.3,1487,0)
 ;;=V72.19^^21^115^1
 ;;^UTILITY(U,$J,358.3,1487,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1487,1,3,0)
 ;;=3^EXAM EARS & HEARING NEC
 ;;^UTILITY(U,$J,358.3,1487,1,4,0)
 ;;=4^V72.19
 ;;^UTILITY(U,$J,358.3,1487,2)
 ;;=^334219
 ;;^UTILITY(U,$J,358.3,1488,0)
 ;;=V72.7^^21^115^71
 ;;^UTILITY(U,$J,358.3,1488,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1488,1,3,0)
 ;;=3^SKIN/SENSITIZATION TESTS
 ;;^UTILITY(U,$J,358.3,1488,1,4,0)
 ;;=4^V72.7
 ;;^UTILITY(U,$J,358.3,1488,2)
 ;;=^295616
 ;;^UTILITY(U,$J,358.3,1489,0)
 ;;=V73.5^^21^115^66
 ;;^UTILITY(U,$J,358.3,1489,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1489,1,3,0)
 ;;=3^SCREENING-ARBOVIRUS DIS
 ;;^UTILITY(U,$J,358.3,1489,1,4,0)
 ;;=4^V73.5
 ;;^UTILITY(U,$J,358.3,1489,2)
 ;;=^295629
 ;;^UTILITY(U,$J,358.3,1490,0)
 ;;=V73.81^^21^115^83
 ;;^UTILITY(U,$J,358.3,1490,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1490,1,3,0)
 ;;=3^SPECIAL SCREEN EXAM HPV
 ;;^UTILITY(U,$J,358.3,1490,1,4,0)
 ;;=4^V73.81
 ;;^UTILITY(U,$J,358.3,1490,2)
 ;;=^335323
 ;;^UTILITY(U,$J,358.3,1491,0)
 ;;=V73.88^^21^115^75
